Oligodeoxynucleotide

Oligodeoxynucleotide (ODN) is a short, single-stranded DNA molecule commonly used in molecular biology and medicine. ODNS are typically composed of 8 to 100 nucleotides and are built from deoxyribonucleotides linked by phosphodiester bonds. In research, they serve as primers for polymerase chain reaction (PCR) and sequencing, and as hybridization probes in blotting, microarrays, and in situ hybridization. In therapeutics, antisense oligonucleotides bind target mRNA to block translation or alter splicing.

ODNs are manufactured by solid-phase phosphoramidite chemistry on automated synthesizers. After synthesis, purification is typically by high-performance liquid chromatography (HPLC) or polyacrylamide gel electrophoresis (PAGE). Natural DNA is susceptible to nuclease degradation and limited cellular uptake, so chemists employ modifications to improve stability and affinity. Common modifications include phosphorothioate backbones and sugar alterations such as 2'-O-methyl or 2'-O-ethyl moieties, as well as more extensive chemistries like locked nucleic acids (LNA). In antisense design, gapmers combine a central DNA region with modified wings to recruit RNase H and enhance potency. Other modifications further improve binding and pharmacokinetic properties.

Applications span basic research, diagnostics, and therapy. ODNs are used as primers and probes in PCR, sequencing, microarrays, and biosensors, and as antisense or splice-switching agents to modulate gene expression. ODN-based therapies face challenges in delivery, tissue distribution, and potential off-target effects or immune activation, but several antisense oligonucleotides have been approved for clinical use in various diseases.